This NIH grant continues the Drug-induced Liver Injury Network (DILIN) Data Coordinating Center. The center provides managerial, logistic, and analytic support for DILIN’s efforts to address drug-induced liver injury (DILI). It also collaborates to identify hepatotoxic ingredients in herbal and dietary supplements. DILI is a challenging condition, and DILIN is a leading resource for understanding its clinical aspects. This funding ensures DILIN’s unique, structured efforts advance DILI understanding, treatment, and prevention, reducing disease burden.
Opportunity ID: 343236
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DK-22-508 |
| Funding Opportunity Title: | Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center (DILIN) (U01 – Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Food and Nutrition Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 24, 2022 |
| Last Updated Date: | Aug 24, 2022 |
| Original Closing Date for Applications: | Oct 27, 2022 |
| Current Closing Date for Applications: | Oct 27, 2022 |
| Archive Date: | Dec 02, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Only the current recipient(s) under RFA-DK-17-510 are eligible to apply to this Funding Opportunity Announcement. Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement is a limited competition for the continuation of the Data Coordinating Center of the Drug-induced Liver Injury Network (DILIN). The Data Coordinating Center will provide managerial, logistic, and analytic functions for the DILIN and build a collaboration with the National Center for Natural Products Research (NCNPR), University of Mississippi to attempt the identification of specific hepatotoxic ingredients in Herbal and Dietary Supplements (HDS) implicated in liver toxicity. This RFA and companion [RFA-DK-22-013, Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 – Clinical Trial Optional)] will seek the continuation of the Data Coordinating Center and several Clinical Centers. Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 19 years, the DILIN through its publications has become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide. The Network has made major advances in the understanding of the clinical presentation and outcomes of liver injury due to drugs as well as herbal and dietary supplements (HDS). These advances have led to exploratory inroads on the pathogenesis of DILI. DILIN remains the only structured, systematic and prospective effort in the United States and world-wide to characterize drug and HDS induced liver injury. The ultimate aims of DILIN are to elucidate the clinical and pathophysiologic features of DILI so as to allow inroads into its understanding, treatment and prevention, thus decreasing the burden of this disease. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-508.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00276554 | Sep 27, 2022 | Oct 27, 2022 | View |
Package 1
Mandatory forms
343236 RR_SF424_5_0-5.0.pdf
343236 PHS398_CoverPageSupplement_5_0-5.0.pdf
343236 RR_OtherProjectInfo_1_4-1.4.pdf
343236 PerformanceSite_4_0-4.0.pdf
343236 RR_KeyPersonExpanded_4_0-4.0.pdf
343236 PHS398_ResearchPlan_4_0-4.0.pdf
343236 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
343236 RR_Budget_3_0-3.0.pdf
343236 RR_SubawardBudget30_3_0-3.0.pdf
343236 PHS398_ModularBudget_1_2-1.2.pdf
343236 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
